ES2842205T3 - Integración de la purificación del ADN y la medición de su metilación y la medición conjunta de mutaciones y/o niveles de expresión de ARNm en un cartucho de reacción automático - Google Patents
Integración de la purificación del ADN y la medición de su metilación y la medición conjunta de mutaciones y/o niveles de expresión de ARNm en un cartucho de reacción automáticoInfo
- Publication number
- ES2842205T3 ES2842205T3 ES16732159T ES16732159T ES2842205T3 ES 2842205 T3 ES2842205 T3 ES 2842205T3 ES 16732159 T ES16732159 T ES 16732159T ES 16732159 T ES16732159 T ES 16732159T ES 2842205 T3 ES2842205 T3 ES 2842205T3
- Authority
- ES
- Spain
- Prior art keywords
- cartridge
- dna
- methylation
- chamber
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 178
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 178
- 238000006243 chemical reaction Methods 0.000 title claims description 166
- 230000014509 gene expression Effects 0.000 title claims description 14
- 238000005259 measurement Methods 0.000 title description 12
- 108020004999 messenger RNA Proteins 0.000 title description 12
- 230000035772 mutation Effects 0.000 title description 12
- 238000000746 purification Methods 0.000 title description 11
- 230000010354 integration Effects 0.000 title description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims abstract description 136
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 131
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 67
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 66
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 66
- 239000011159 matrix material Substances 0.000 claims abstract description 32
- 239000012530 fluid Substances 0.000 claims abstract description 29
- 238000010438 heat treatment Methods 0.000 claims abstract description 26
- 239000000872 buffer Substances 0.000 claims abstract description 22
- 230000006326 desulfonation Effects 0.000 claims abstract description 20
- 238000005869 desulfonation reaction Methods 0.000 claims abstract description 20
- 238000004891 communication Methods 0.000 claims abstract description 19
- 238000010828 elution Methods 0.000 claims abstract description 15
- 239000000523 sample Substances 0.000 claims description 342
- 108020004414 DNA Proteins 0.000 claims description 217
- 238000001514 detection method Methods 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000243 solution Substances 0.000 claims description 44
- 108091006146 Channels Proteins 0.000 claims description 38
- 230000002441 reversible effect Effects 0.000 claims description 27
- 239000011324 bead Substances 0.000 claims description 24
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 238000007855 methylation-specific PCR Methods 0.000 claims description 20
- 101710099902 Acid-sensing ion channel 2 Proteins 0.000 claims description 17
- 108091005660 ADAMTS1 Proteins 0.000 claims description 16
- 102000051388 ADAMTS1 Human genes 0.000 claims description 16
- 239000000975 dye Substances 0.000 claims description 15
- -1 RASSF1A Proteins 0.000 claims description 14
- 238000003776 cleavage reaction Methods 0.000 claims description 14
- 230000007017 scission Effects 0.000 claims description 14
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 claims description 12
- 102100034535 Histone H3.1 Human genes 0.000 claims description 12
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 claims description 12
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 claims description 12
- 102100028404 Homeobox protein Hox-B4 Human genes 0.000 claims description 11
- 101000839788 Homo sapiens Homeobox protein Hox-B4 Proteins 0.000 claims description 11
- 101000580043 Homo sapiens Ras-specific guanine nucleotide-releasing factor 2 Proteins 0.000 claims description 10
- 101000648534 Homo sapiens Transmembrane 6 superfamily member 1 Proteins 0.000 claims description 10
- 102100027555 Ras-specific guanine nucleotide-releasing factor 2 Human genes 0.000 claims description 10
- 102100028864 Transmembrane 6 superfamily member 1 Human genes 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 7
- 108060004795 Methyltransferase Proteins 0.000 claims description 7
- 102000016397 Methyltransferase Human genes 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- YQRQRUBEHCXCPR-UHFFFAOYSA-M cesium hydrogen sulfite Chemical compound [Cs+].OS([O-])=O YQRQRUBEHCXCPR-UHFFFAOYSA-M 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 claims description 5
- 229940099427 potassium bisulfite Drugs 0.000 claims description 5
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000012149 elution buffer Substances 0.000 claims description 4
- RWISEVUOFYXWFO-UHFFFAOYSA-N 1,4-diazoniabicyclo[2.2.2]octane-1,4-disulfinate Chemical compound C1C[N+]2(S([O-])=O)CC[N+]1(S(=O)[O-])CC2 RWISEVUOFYXWFO-UHFFFAOYSA-N 0.000 claims description 3
- 108010006785 Taq Polymerase Proteins 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 108010037497 3'-nucleotidase Proteins 0.000 claims 1
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 claims 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 1
- IVJAMOKTEMXQNV-UHFFFAOYSA-N ethanol;guanidine Chemical compound CCO.NC(N)=N IVJAMOKTEMXQNV-UHFFFAOYSA-N 0.000 claims 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 91
- 238000003752 polymerase chain reaction Methods 0.000 description 68
- 238000004458 analytical method Methods 0.000 description 66
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 51
- 230000007067 DNA methylation Effects 0.000 description 50
- 238000003556 assay Methods 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 41
- 238000011529 RT qPCR Methods 0.000 description 38
- 238000012545 processing Methods 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 32
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 31
- 238000009396 hybridization Methods 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 27
- 230000003321 amplification Effects 0.000 description 26
- 230000009089 cytolysis Effects 0.000 description 26
- 238000003199 nucleic acid amplification method Methods 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 25
- 230000000670 limiting effect Effects 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 239000000203 mixture Substances 0.000 description 22
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 18
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 18
- 238000012163 sequencing technique Methods 0.000 description 18
- 239000007983 Tris buffer Substances 0.000 description 16
- 102100027904 Zinc finger protein basonuclin-1 Human genes 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 101150072950 BRCA1 gene Proteins 0.000 description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 13
- 201000002528 pancreatic cancer Diseases 0.000 description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 description 13
- 108700020463 BRCA1 Proteins 0.000 description 12
- 102000036365 BRCA1 Human genes 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 229940104302 cytosine Drugs 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000012408 PCR amplification Methods 0.000 description 10
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 108091029430 CpG site Proteins 0.000 description 9
- 108010067770 Endopeptidase K Proteins 0.000 description 9
- 101710189720 Porphobilinogen deaminase Proteins 0.000 description 9
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 9
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000007857 nested PCR Methods 0.000 description 9
- 238000012175 pyrosequencing Methods 0.000 description 9
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 9
- 229940035893 uracil Drugs 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 7
- 239000012670 alkaline solution Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000000937 inactivator Effects 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 108091029523 CpG island Proteins 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 101150042248 Mgmt gene Proteins 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000006607 hypermethylation Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000007834 ligase chain reaction Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000007899 nucleic acid hybridization Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- DJLUSNAYRNFVSM-UHFFFAOYSA-N methyl 2-(2,4-dioxo-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=CNC(=O)NC1=O DJLUSNAYRNFVSM-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 102100033792 ALX homeobox protein 1 Human genes 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 3
- 101000779615 Homo sapiens ALX homeobox protein 1 Proteins 0.000 description 3
- 101000603407 Homo sapiens Neuropeptides B/W receptor type 1 Proteins 0.000 description 3
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 3
- 101000601991 Homo sapiens Protocadherin gamma-B6 Proteins 0.000 description 3
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102100038847 Neuropeptides B/W receptor type 1 Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 102100037542 Protocadherin gamma-B6 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000009615 deamination Effects 0.000 description 3
- 238000006481 deamination reaction Methods 0.000 description 3
- 239000013530 defoamer Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000019000 fluorine Nutrition 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- 101150087690 ACTB gene Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 2
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102100034523 Histone H4 Human genes 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 2
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012204 single target assay Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- YOVIGIMYOOIFQP-UHFFFAOYSA-N 1h-pyrimidine-2,4-dione;sulfurous acid Chemical class OS(O)=O.O=C1C=CNC(=O)N1 YOVIGIMYOOIFQP-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- UACOJOVKHNAJPX-UHFFFAOYSA-N 5-(methoxyamino)-6-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CONC=1C(NC(NC=1C)=S)=O UACOJOVKHNAJPX-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- UHJIRFAYZBNOHS-UHFFFAOYSA-N BNCl Chemical compound BNCl UHJIRFAYZBNOHS-UHFFFAOYSA-N 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100035342 Cysteine dioxygenase type 1 Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101150034920 Hmbs gene Proteins 0.000 description 1
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 description 1
- 101000737778 Homo sapiens Cysteine dioxygenase type 1 Proteins 0.000 description 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical class CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010076693 O(6)-Methylguanine-DNA Methyltransferase Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- OTYCIBMYFBOSMG-XNIJJKJLSA-N [[(2r,3s,4r,5r)-5-[6-(6-aminohexylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(NCCCCCCN)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O OTYCIBMYFBOSMG-XNIJJKJLSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- SWSSJIPVPWGWOQ-UHFFFAOYSA-N carbamimidoylazanium;ethanol;thiocyanate Chemical compound CCO.[S-]C#N.NC([NH3+])=N SWSSJIPVPWGWOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 208000028610 heart and brain malformation syndrome Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000004226 microchip electrophoresis Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 102100032270 tRNA (cytosine(38)-C(5))-methyltransferase Human genes 0.000 description 1
- 101710184308 tRNA (cytosine(38)-C(5))-methyltransferase Proteins 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Clinical Laboratory Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175916P | 2015-06-15 | 2015-06-15 | |
| PCT/US2016/037422 WO2016205233A2 (en) | 2015-06-15 | 2016-06-14 | Integrated purification and measurement of dna methylation and co-measurement of mutations and/or mrna expression levels in an automated reaction cartridge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2842205T3 true ES2842205T3 (es) | 2021-07-13 |
Family
ID=56204035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16732159T Active ES2842205T3 (es) | 2015-06-15 | 2016-06-14 | Integración de la purificación del ADN y la medición de su metilación y la medición conjunta de mutaciones y/o niveles de expresión de ARNm en un cartucho de reacción automático |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11603555B2 (https=) |
| EP (2) | EP3307885B1 (https=) |
| JP (2) | JP7020922B2 (https=) |
| CN (1) | CN107922941A (https=) |
| AU (3) | AU2016277943B2 (https=) |
| CA (1) | CA2989573A1 (https=) |
| ES (1) | ES2842205T3 (https=) |
| WO (1) | WO2016205233A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10233440B2 (en) | 2012-09-28 | 2019-03-19 | Cepheid | Methods for DNA and RNA extraction from fixed paraffin-embedded tissue samples |
| WO2016205233A2 (en) | 2015-06-15 | 2016-12-22 | Cepheid | Integrated purification and measurement of dna methylation and co-measurement of mutations and/or mrna expression levels in an automated reaction cartridge |
| DE102015009187B3 (de) * | 2015-07-16 | 2016-10-13 | Dimo Dietrich | Verfahren zur Bestimmung einer Mutation in genomischer DNA, Verwendung des Verfahrens und Kit zur Durchführung des Verfahrens |
| AU2016298048B2 (en) * | 2015-07-24 | 2022-08-04 | Cepheid | Compositions and methods for DNA and RNA extraction from tissue samples |
| MX2019006628A (es) * | 2016-12-12 | 2019-11-12 | Cepheid | Purificacion y medicion integradas de metilacion de adn y co-medicion de mutaciones y/o niveles de expresion de arnm en un cartucho de reaccion automatizado. |
| CN108277274A (zh) * | 2017-01-03 | 2018-07-13 | 博尔诚（北京）科技有限公司 | 用于区分胰腺癌和慢性胰腺炎的组合物及其用途 |
| US20200010907A1 (en) * | 2017-03-17 | 2020-01-09 | Mdxhealth Sa | Mgmt epigenetic deep-sequencing assay |
| CN107164535A (zh) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | 一种无创高通量甲基化结肠癌诊断、研究和治疗方法 |
| US11466323B2 (en) * | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
| US11207674B2 (en) | 2017-08-09 | 2021-12-28 | Biogx, Inc. | Method of customizing a universal reagent cartridge with a lyophilized target-specific reagent |
| SG11202001209QA (en) * | 2017-08-25 | 2020-03-30 | Sekisui Medical Co Ltd | Chromatography packing for separation and/or detection of methylated dna |
| CN107868813B (zh) * | 2017-11-16 | 2021-07-27 | 上海覃谷生物技术有限公司 | 一种血浆dna边提取边转化的方法及应用 |
| CN119753091A (zh) | 2018-04-02 | 2025-04-04 | 格里尔公司 | 用于扩增与癌症相关联的cfDNA分子的化验板 |
| CN108300787A (zh) * | 2018-04-17 | 2018-07-20 | 中国科学院北京基因组研究所 | 特异甲基化位点作为乳腺癌早期诊断标志物的应用 |
| CN108531595A (zh) * | 2018-04-25 | 2018-09-14 | 新疆医科大学附属肿瘤医院 | 检测待测dna甲基化的引物组合物、检测方法及应用 |
| CN108456721B (zh) * | 2018-05-16 | 2021-07-09 | 基因科技（上海）股份有限公司 | 同步检测基因突变和甲基化的方法及其应用 |
| CN108676879A (zh) * | 2018-05-24 | 2018-10-19 | 中国科学院北京基因组研究所 | 特异甲基化位点作为乳腺癌分子分型诊断标志物的应用 |
| CN108796080B (zh) * | 2018-06-06 | 2022-06-07 | 苏州唯善生物科技有限公司 | 用于结直肠癌诊断、检测或筛查的引物和探针组 |
| CN108753979B (zh) * | 2018-07-09 | 2021-10-26 | 安徽达健医学科技有限公司 | 一种用于肝癌早期筛查的试剂盒及其使用方法 |
| CN112585282A (zh) * | 2018-07-26 | 2021-03-30 | 北京艾克伦医疗科技有限公司 | 鉴定乳腺癌状态的方法和试剂盒 |
| IL281741B2 (en) | 2018-09-27 | 2026-04-01 | Grail Inc | Methylation markers and a targeted methylation detection panel |
| CN110964813B (zh) * | 2018-09-29 | 2021-11-16 | 广州康立明生物科技股份有限公司 | Hoxa7甲基化检测试剂在制备肺癌诊断试剂中的用途 |
| CN111088351A (zh) * | 2018-10-23 | 2020-05-01 | 博尔诚（北京）科技有限公司 | 用于检测肺癌的组合物及其用途 |
| WO2020252721A1 (en) * | 2019-06-20 | 2020-12-24 | The Johns Hopkins University | Dna methylation markers and their use in differentiation of suspected cancerous lymph node biopsy samples |
| WO2020257404A1 (en) * | 2019-06-20 | 2020-12-24 | The Johns Hopkins University | Dna markers for differentiation of biopsy samples |
| CN111676287B (zh) * | 2020-06-03 | 2022-04-29 | 广州康立明生物科技股份有限公司 | 一种基因标志物组合及其应用 |
| CN111662980A (zh) * | 2020-06-03 | 2020-09-15 | 广州市康立明生物科技有限责任公司 | 一种肺癌检测试剂及试剂盒 |
| CN113930499B (zh) * | 2020-06-29 | 2023-09-22 | 武汉艾米森生命科技有限公司 | 检测基因甲基化的试剂的应用以及结直肠癌诊断或辅助诊断试剂盒 |
| CN114085894A (zh) * | 2021-11-03 | 2022-02-25 | 翌圣生物科技(上海)股份有限公司 | 核酸甲基化胞嘧啶转化方法 |
| WO2023133533A2 (en) * | 2022-01-06 | 2023-07-13 | The University Of Chicago | Methods and compositions for rapid detection and analysis of rna and dna cytosine methylation |
| DE102022204638B4 (de) | 2022-05-12 | 2025-01-02 | Robert Bosch Gesellschaft mit beschränkter Haftung | Verfahren und mikrofluidische Vorrichtung zur Denaturierung einer Nukleinsäure |
| EP4299764A1 (en) * | 2022-06-28 | 2024-01-03 | Universal Diagnostics, S.A. | Methods for detecting pancreatic cancer using dna methylation markers |
| WO2024111038A1 (ja) * | 2022-11-22 | 2024-05-30 | 株式会社日立ハイテク | 変異遺伝子検出方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1190838A (en) | 1981-07-17 | 1985-07-23 | Cavit Akin | Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer |
| US5449602A (en) | 1988-01-13 | 1995-09-12 | Amoco Corporation | Template-directed photoligation |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| EP2332958B1 (en) | 1996-02-09 | 2016-04-20 | Cornell Research Foundation, Inc. | Detection of nucleic and sequence differences using the ligase detection reaction with addressable arrays |
| EP0892808B1 (en) | 1996-04-12 | 2008-05-14 | PHRI Properties, Inc. | Detection probes, kits and assays |
| EP1736554B1 (en) | 1996-05-29 | 2013-10-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6312892B1 (en) | 1996-07-19 | 2001-11-06 | Cornell Research Foundation, Inc. | High fidelity detection of nucleic acid differences by ligase detection reaction |
| US5958349A (en) | 1997-02-28 | 1999-09-28 | Cepheid | Reaction vessel for heat-exchanging chemical processes |
| US6251594B1 (en) * | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
| US6027998A (en) | 1997-12-17 | 2000-02-22 | Advanced Micro Devices, Inc. | Method for fully planarized conductive line for a stack gate |
| DK1179585T3 (da) | 1997-12-24 | 2008-11-10 | Cepheid | Indretning og fremgangsmåde til lysis |
| US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US6942771B1 (en) * | 1999-04-21 | 2005-09-13 | Clinical Micro Sensors, Inc. | Microfluidic systems in the electrochemical detection of target analytes |
| US6818185B1 (en) | 1999-05-28 | 2004-11-16 | Cepheid | Cartridge for conducting a chemical reaction |
| JP4078073B2 (ja) | 1999-05-28 | 2008-04-23 | シーフィード | 流体試料分析装置および方法 |
| US6403037B1 (en) | 2000-02-04 | 2002-06-11 | Cepheid | Reaction vessel and temperature control system |
| EP1313880A2 (en) | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6605451B1 (en) | 2000-06-06 | 2003-08-12 | Xtrana, Inc. | Methods and devices for multiplexing amplification reactions |
| US20060134643A1 (en) * | 2000-06-19 | 2006-06-22 | Kurt Berlin | Bisulfite conversion of DNA |
| DE10112515B4 (de) | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| JP2003144172A (ja) * | 2001-11-16 | 2003-05-20 | Nisshinbo Ind Inc | メチル化検出用オリゴヌクレオチド固定化基板 |
| US9394332B2 (en) | 2002-08-29 | 2016-07-19 | Epigenomics Ag | Method for bisulfite treatment |
| US7288373B2 (en) * | 2003-05-02 | 2007-10-30 | Human Genetic Signatures Pty Ltd. | Treatment of methylated nucleic acid |
| WO2005042713A2 (en) | 2003-10-28 | 2005-05-12 | The Johns Hopkins University | Quantitative multiplex methylation-specific pcr |
| EP2261650A3 (en) | 2004-09-15 | 2011-07-06 | IntegenX Inc. | Microfluidic devices |
| US20060068399A1 (en) | 2004-09-24 | 2006-03-30 | Cepheid | Multiple bead reagent system for protein based assays with optimized matrices |
| ES2647483T3 (es) * | 2005-04-01 | 2017-12-21 | Epigenomics Ag | Conversión por bisulfito mejorada de ADN |
| US20060286577A1 (en) * | 2005-06-17 | 2006-12-21 | Xiyu Jia | Methods for detection of methylated DNA |
| ES2373686T3 (es) | 2005-06-23 | 2012-02-07 | Biocartis Sa | Cartucho, sistema y procedimiento para diagnósticos médicos automatizados. |
| US8703476B2 (en) * | 2005-06-30 | 2014-04-22 | Biocartis Sa | Cartridge for automated medical diagnostics |
| EP1963352B1 (en) * | 2005-12-14 | 2010-09-08 | Roche Diagnostics GmbH | New method for bisulfite treatment |
| JP5063616B2 (ja) * | 2006-02-03 | 2012-10-31 | インテジェニックス インコーポレイテッド | マイクロ流体デバイス |
| US20090036665A1 (en) * | 2007-07-11 | 2009-02-05 | Gonzalo Domingo | Disposable Sample Processing Unit |
| CN101802223A (zh) | 2007-08-15 | 2010-08-11 | 香港大学 | 用于高通量亚硫酸氢盐dna-测序的方法和组合物及其用途 |
| KR20110030415A (ko) | 2008-01-22 | 2011-03-23 | 인터젠엑스 인크. | 만능 샘플 제조 시스템 및 집적 분석 시스템에서의 용도 |
| FR2928659B1 (fr) * | 2008-03-12 | 2012-01-13 | Biomerieux Sa | Procede pour le diagnostic ou pronostic in vitro du cancer du testicule |
| CN101285096A (zh) | 2008-06-03 | 2008-10-15 | 中国人民解放军第二军医大学 | 一种快速检测dna甲基化的方法 |
| US20120252015A1 (en) * | 2011-02-18 | 2012-10-04 | Bio-Rad Laboratories | Methods and compositions for detecting genetic material |
| EP2218793A1 (en) | 2009-02-13 | 2010-08-18 | Alphagenics International SA | Detection of MGMT methylation in tumors |
| CN102612652B (zh) * | 2009-08-06 | 2016-05-04 | 康奈尔大学 | 用于分子分析的设备和方法 |
| PL2539450T3 (pl) * | 2010-02-25 | 2016-08-31 | Advanced Liquid Logic Inc | Sposób wytwarzania bibliotek kwasu nukleinowego |
| GB201004147D0 (en) | 2010-03-12 | 2010-04-28 | Dna Electronics Ltd | Method and apparatus for sensing methylation |
| CN101984069B (zh) | 2010-09-19 | 2012-07-25 | 生工生物工程(上海)有限公司 | 一种快速检测dna甲基化的试剂盒及方法 |
| US20150136604A1 (en) * | 2011-10-21 | 2015-05-21 | Integenx Inc. | Sample preparation, processing and analysis systems |
| US10132728B2 (en) | 2012-04-27 | 2018-11-20 | Cepheid | Apparatus with heterogeneous processing modules |
| WO2013177265A1 (en) | 2012-05-22 | 2013-11-28 | The Johns Hopkins University | A QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE |
| US20150154352A1 (en) * | 2012-06-21 | 2015-06-04 | Gigagen, Inc. | System and Methods for Genetic Analysis of Mixed Cell Populations |
| CN104737024B (zh) * | 2012-09-05 | 2018-01-09 | 塞弗德公司 | 流体分析系统中的通用对接站和数据门 |
| US10233440B2 (en) | 2012-09-28 | 2019-03-19 | Cepheid | Methods for DNA and RNA extraction from fixed paraffin-embedded tissue samples |
| US20140272967A1 (en) | 2013-03-13 | 2014-09-18 | Abbott Molecular Inc. | Systems and methods for isolating nucleic acids |
| EP2971171A4 (en) * | 2013-03-14 | 2016-11-02 | Abbott Molecular Inc | SYSTEMS AND METHODS FOR MULTIPLEX AMPLIFICATION SPECIFIC TO METHYLATION |
| US9670479B2 (en) | 2013-03-15 | 2017-06-06 | F Cubed, LLC | Sample preparation device and methods of use |
| EP2971032B1 (en) * | 2013-03-15 | 2019-05-08 | Abbott Molecular Inc. | Compositions and methods for nucleic acid extraction |
| GB201316347D0 (en) | 2013-09-13 | 2013-10-30 | Cancer Rec Tech Ltd | Biological fluid filtration assembly |
| KR20150038944A (ko) | 2013-10-01 | 2015-04-09 | 주식회사 바이오이즈 | 유전자의 메틸화 여부 및 비율의 분석방법 |
| US20150099670A1 (en) * | 2013-10-07 | 2015-04-09 | Weiwei Li | Method of preparing post-bisulfite conversion DNA library |
| ES2815684T3 (es) | 2015-06-10 | 2021-03-30 | Biocartis N V | Detección mejorada de ADN metilado |
| WO2016205233A2 (en) | 2015-06-15 | 2016-12-22 | Cepheid | Integrated purification and measurement of dna methylation and co-measurement of mutations and/or mrna expression levels in an automated reaction cartridge |
| MX2019006628A (es) | 2016-12-12 | 2019-11-12 | Cepheid | Purificacion y medicion integradas de metilacion de adn y co-medicion de mutaciones y/o niveles de expresion de arnm en un cartucho de reaccion automatizado. |
-
2016
- 2016-06-14 WO PCT/US2016/037422 patent/WO2016205233A2/en not_active Ceased
- 2016-06-14 JP JP2017564901A patent/JP7020922B2/ja active Active
- 2016-06-14 CA CA2989573A patent/CA2989573A1/en active Pending
- 2016-06-14 CN CN201680048155.XA patent/CN107922941A/zh active Pending
- 2016-06-14 EP EP16732159.5A patent/EP3307885B1/en active Active
- 2016-06-14 EP EP20202659.7A patent/EP3839047A1/en active Pending
- 2016-06-14 ES ES16732159T patent/ES2842205T3/es active Active
- 2016-06-14 AU AU2016277943A patent/AU2016277943B2/en active Active
- 2016-06-14 US US15/182,394 patent/US11603555B2/en active Active
-
2022
- 2022-02-02 JP JP2022014857A patent/JP7466580B2/ja active Active
- 2022-11-30 AU AU2022279465A patent/AU2022279465B2/en active Active
-
2023
- 2023-01-11 US US18/095,982 patent/US20240141415A1/en active Pending
-
2025
- 2025-06-16 AU AU2025204463A patent/AU2025204463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016205233A2 (en) | 2016-12-22 |
| JP7466580B2 (ja) | 2024-04-12 |
| AU2025204463A1 (en) | 2025-07-03 |
| JP7020922B2 (ja) | 2022-02-16 |
| CA2989573A1 (en) | 2016-12-22 |
| AU2016277943A1 (en) | 2018-02-01 |
| EP3307885A2 (en) | 2018-04-18 |
| AU2016277943B2 (en) | 2022-09-01 |
| JP2018524978A (ja) | 2018-09-06 |
| US11603555B2 (en) | 2023-03-14 |
| US20170137871A1 (en) | 2017-05-18 |
| EP3307885B1 (en) | 2020-10-21 |
| EP3839047A1 (en) | 2021-06-23 |
| AU2022279465A1 (en) | 2023-02-02 |
| WO2016205233A3 (en) | 2017-02-02 |
| JP2022070885A (ja) | 2022-05-13 |
| AU2022279465B2 (en) | 2025-04-10 |
| CN107922941A (zh) | 2018-04-17 |
| US20240141415A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2842205T3 (es) | Integración de la purificación del ADN y la medición de su metilación y la medición conjunta de mutaciones y/o niveles de expresión de ARNm en un cartucho de reacción automático | |
| US12539510B2 (en) | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge | |
| ES2769841T3 (es) | Método de análisis de metilación | |
| ES2890776T3 (es) | Métodos, composiciones y kits para la captura, la detección y la cuantificación del ARN pequeño | |
| ES2538214T3 (es) | Un método para el análisis de metilación de ácido nucleico | |
| CN109072310A (zh) | 在尿液中检测癌症 | |
| ES2950346T3 (es) | Detección mejorada de repeticiones homopoliméricas cortas | |
| CN102016067A (zh) | 前列腺癌中gstp1高甲基化的检测 | |
| US8377657B1 (en) | Primers for analyzing methylated sequences and methods of use thereof | |
| US20130309667A1 (en) | Primers for analyzing methylated sequences and methods of use thereof | |
| US9765397B2 (en) | Method of detecting methylation | |
| US20080096213A1 (en) | Method for confirming conversion treatment and nucleic acid molecule used therefor | |
| RU2780660C2 (ru) | ОБЪЕДИНЕННАЯ ОЧИСТКА И ИЗМЕРЕНИЕ МЕТИЛИРОВАНИЯ ДНК С СОВМЕСТНЫМ ИЗМЕРЕНИЕМ МУТАЦИЙ И/ИЛИ УРОВНЕЙ ЭКСПРЕССИИ мРНК В АВТОМАТИЧЕСКОМ РЕАКЦИОННОМ КАРТРИДЖЕ | |
| BR112019011670B1 (pt) | Conjunto de cartuchos e método para determinação do estado de metilação de um ácido nucleico, sistema para determinação da metilação de um ácido nucleico em uma amostra biológica, método para detecção de um câncer ou da predisposição a um câncer em um indivíduo, e kit para determinação de metilação do dna | |
| US20130310550A1 (en) | Primers for analyzing methylated sequences and methods of use thereof | |
| HK40013640A (en) | Integrated purification and measurement of dna methylation and co-measurement of mutations and/or mrna expression levels in an automated reaction cartridge |